Literature DB >> 15942360

Topical inhibition of nuclear factor-kappaB enhances reduction in lung edema by surfactant in a piglet model of airway lavage.

Tobias Ankermann1, Anja Reisner, Tina Wiemann, Matthias Krams, Heike Köhler, Martin F Krause.   

Abstract

OBJECTIVE: Acute respiratory distress syndrome is occasionally seen in newborn infants due to a severe inflammatory process in the lungs that affects capillary-alveolar permeability, epithelial integrity, and type I and II pneumocyte function. The aim of this study was to investigate the effect of a topically applied nuclear factor-kappaB inhibitor (IkappaB kinase-NF-kappaB essential modulator binding domain [IKK-NBD] peptide) on gas exchange, lung function, lung fluids, and inflammation in a piglet model of repeated airway lavage that is characterized by surfactant deficiency, lung edema, and an inflammatory response.
DESIGN: Prospective, randomized, controlled animal study.
SETTING: Research laboratory of a university children's hospital.
SUBJECTS: A total of 24 anesthetized, mechanically ventilated newborn piglets.
INTERVENTIONS: Repeated airway lavage was carried out until both the Pao2 decreased to approximately 40 mm Hg, while ventilating the piglets with an Fio2 of 0.6, and a peak inspiratory pressure of >/=18 cm H2O was needed to maintain tidal volume at 6 mL/kg. One group of piglets served as a control (n = 8), a second group (S, n = 8) received a porcine surfactant preparation (Curosurf), and a third group received IKK-NBD peptide admixed to surfactant (S+IN, n = 8).
MEASUREMENTS AND MAIN RESULTS: After 6 hrs of mechanical ventilation after intervention, S+IN group piglets showed decreased extravascular lung water (S+IN vs. S, 20 +/- 3 vs. 28 +/- 10 mL/kg; p < .05) and a lesser protein content in the epithelial lining fluid (S+IN vs. S, 38 +/- 5 vs. 50 +/- 5 mg/L; p < .05). Functional residual capacity (S+IN vs. S, 16.7 +/- 6.3 vs. 12.2 +/- 4.3 mL/kg; p < .05), alveolar volume (S+IN vs. S, 5.4 +/- 1.8 vs. 4.6 +/- 1.5 mL/kg; p < .05), and lung mechanics were improved. Bronchoalveolar lavage showed a lesser percentage of polymorphonuclear leukocytes (S+IN vs. S, 70% +/- 6% vs. 82% +/- 3%; p < .01) and a reduction in the chemokine leukotriene B4 (S+IN vs. S, 2.0 +/- 0.6 vs. 3.5 +/- 1.4 pg/mL; p < .01).
CONCLUSIONS: A topically applied nuclear factor-kappaB inhibitor improves lung edema and lung volumes and reduces inflammation in this newborn piglet model of airway lavage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942360     DOI: 10.1097/01.ccm.0000166371.18066.5e

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

1.  Hyperoxia-induced NF-kappaB activation occurs via a maturationally sensitive atypical pathway.

Authors:  Clyde J Wright; Tiangang Zhuang; Ping La; Guang Yang; Phyllis A Dennery
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-12-12       Impact factor: 5.464

2.  NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.

Authors:  Anita Gaurnier-Hausser; Reema Patel; Albert S Baldwin; Michael J May; Nicola J Mason
Journal:  Clin Cancer Res       Date:  2011-05-24       Impact factor: 12.531

3.  Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.

Authors:  Ainhoa Oguiza; Carlota Recio; Iolanda Lazaro; Beñat Mallavia; Julia Blanco; Jesus Egido; Carmen Gomez-Guerrero
Journal:  Diabetologia       Date:  2015-04-28       Impact factor: 10.122

Review 4.  Cell penetrating peptide inhibitors of nuclear factor-kappa B.

Authors:  J S Orange; M J May
Journal:  Cell Mol Life Sci       Date:  2008-11       Impact factor: 9.261

Review 5.  The IkappaB kinase complex: master regulator of NF-kappaB signaling.

Authors:  Laura A Solt; Michael J May
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.

Authors:  Georges Habineza Ndikuyeze; Anita Gaurnier-Hausser; Reema Patel; Albert S Baldwin; Michael J May; Patrick Flood; Erika Krick; Kathleen J Propert; Nicola J Mason
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

7.  Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation.

Authors:  Jing Zhao; Lei Zhang; Xiaodong Mu; Christelle Doebelin; William Nguyen; Callen Wallace; Daniel P Reay; Sara J McGowan; Lana Corbo; Paula R Clemens; Gabriela Mustata Wilson; Simon C Watkins; Laura A Solt; Michael D Cameron; Johnny Huard; Laura J Niedernhofer; Theodore M Kamenecka; Paul D Robbins
Journal:  PLoS Biol       Date:  2018-06-11       Impact factor: 8.029

8.  An Unsettled Promise: The Newborn Piglet Model of Neonatal Acute Respiratory Distress Syndrome (NARDS). Physiologic Data and Systematic Review.

Authors:  Dietmar Spengler; Nele Rintz; Martin F Krause
Journal:  Front Physiol       Date:  2019-10-30       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.